{"transactions":[{"id":1843594,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":111884,"kind":"organization","name":"Caissa Capital Management ltd.","position":1,"cik":"0001929354","reported_name":"Caissa Capital Management ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-06-27T16:10:55.000Z","date":"2023-06-26","kind":"purchase","planned":false,"acquired":false,"shares":182300,"price":0.62,"value":113026.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"These shares are directly owned by Mr. Golestaneh in his personal capacity."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001929354-23-000016","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1929354/000192935423000016/primary_doc.xml","form_type":"4"}},{"id":1843593,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":111884,"kind":"organization","name":"Caissa Capital Management ltd.","position":1,"cik":"0001929354","reported_name":"Caissa Capital Management ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-06-27T16:10:55.000Z","date":"2023-06-26","kind":"purchase","planned":false,"acquired":false,"shares":1425700,"price":0.6433,"value":917152.81,"ownership":{"direct":false,"nature":"See Footnote (1)"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.45 to $0.84, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Shares held by Caissa Capital Management Ltd, a British Virgin Islands company controlled by Mr. Golestaneh."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001929354-23-000016","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1929354/000192935423000016/primary_doc.xml","form_type":"4"}},{"id":1850059,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":111884,"kind":"organization","name":"Caissa Capital Management ltd.","position":1,"cik":"0001929354","reported_name":"Caissa Capital Management ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-06-20T16:04:50.000Z","date":"2023-06-20","kind":"purchase","planned":false,"acquired":true,"shares":2000,"price":4.1444,"value":8288.8,"ownership":{"direct":false,"nature":"See Footnote (1)"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.07 to $4.17, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Shares held by Caissa Capital Management Ltd, a British Virgin Islands company controlled by Mr. Golestaneh."}],"balance_after":1425700,"source":{"system":"sec-edgar","filing":"0001929354-23-000015","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1929354/000192935423000015/primary_doc.xml","form_type":"4"}},{"id":1850058,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":111884,"kind":"organization","name":"Caissa Capital Management ltd.","position":1,"cik":"0001929354","reported_name":"Caissa Capital Management ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-06-20T16:04:50.000Z","date":"2023-06-16","kind":"purchase","planned":false,"acquired":true,"shares":3000,"price":3.9048,"value":11714.4,"ownership":{"direct":false,"nature":"See Footnote (1)"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.745 to $3.98, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Shares held by Caissa Capital Management Ltd, a British Virgin Islands company controlled by Mr. Golestaneh."}],"balance_after":1423700,"source":{"system":"sec-edgar","filing":"0001929354-23-000015","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1929354/000192935423000015/primary_doc.xml","form_type":"4"}},{"id":1850057,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":111884,"kind":"organization","name":"Caissa Capital Management ltd.","position":1,"cik":"0001929354","reported_name":"Caissa Capital Management ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-06-20T16:04:50.000Z","date":"2023-06-15","kind":"purchase","planned":false,"acquired":true,"shares":3160,"price":3.6837,"value":11640.492,"ownership":{"direct":false,"nature":"See Footnote (1)"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.19 to $3.99, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Shares held by Caissa Capital Management Ltd, a British Virgin Islands company controlled by Mr. Golestaneh."}],"balance_after":1420700,"source":{"system":"sec-edgar","filing":"0001929354-23-000015","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1929354/000192935423000015/primary_doc.xml","form_type":"4"}},{"id":1856133,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":111884,"kind":"organization","name":"Caissa Capital Management ltd.","position":1,"cik":"0001929354","reported_name":"Caissa Capital Management ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-06-14T16:14:07.000Z","date":"2023-06-14","kind":"purchase","planned":false,"acquired":true,"shares":6000,"price":3.479,"value":20874.0,"ownership":{"direct":false,"nature":"See Footnote (1)"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.245 to $3.55, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Shares held by Caissa Capital Management Ltd, a British Virgin Islands company controlled by Mr. Golestaneh."}],"balance_after":1417540,"source":{"system":"sec-edgar","filing":"0001929354-23-000014","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1929354/000192935423000014/primary_doc.xml","form_type":"4"}},{"id":1856132,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":111884,"kind":"organization","name":"Caissa Capital Management ltd.","position":1,"cik":"0001929354","reported_name":"Caissa Capital Management ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-06-14T16:14:07.000Z","date":"2023-06-13","kind":"purchase","planned":false,"acquired":true,"shares":8750,"price":3.8216,"value":33439.0,"ownership":{"direct":false,"nature":"See Footnote (1)"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.7 to $3.83, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Shares held by Caissa Capital Management Ltd, a British Virgin Islands company controlled by Mr. Golestaneh."}],"balance_after":1411540,"source":{"system":"sec-edgar","filing":"0001929354-23-000014","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1929354/000192935423000014/primary_doc.xml","form_type":"4"}},{"id":1856131,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":111884,"kind":"organization","name":"Caissa Capital Management ltd.","position":1,"cik":"0001929354","reported_name":"Caissa Capital Management ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-06-14T16:14:07.000Z","date":"2023-06-12","kind":"purchase","planned":false,"acquired":true,"shares":2149,"price":4.3352,"value":9316.3448,"ownership":{"direct":false,"nature":"See Footnote (1)"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.125 to $4.47, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Shares held by Caissa Capital Management Ltd, a British Virgin Islands company controlled by Mr. Golestaneh."}],"balance_after":1402790,"source":{"system":"sec-edgar","filing":"0001929354-23-000014","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1929354/000192935423000014/primary_doc.xml","form_type":"4"}},{"id":1860955,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":111884,"kind":"organization","name":"Caissa Capital Management ltd.","position":1,"cik":"0001929354","reported_name":"Caissa Capital Management ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-06-09T16:24:16.000Z","date":"2023-06-09","kind":"purchase","planned":false,"acquired":true,"shares":5044,"price":4.1427,"value":20895.7788,"ownership":{"direct":false,"nature":"See Footnote (1)"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.01 to $4.3, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Shares held by Caissa Capital Management Ltd, a British Virgin Islands company controlled by Mr. Golestaneh."}],"balance_after":1400641,"source":{"system":"sec-edgar","filing":"0001929354-23-000013","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1929354/000192935423000013/primary_doc.xml","form_type":"4"}},{"id":1860954,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":111884,"kind":"organization","name":"Caissa Capital Management ltd.","position":1,"cik":"0001929354","reported_name":"Caissa Capital Management ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-06-09T16:24:16.000Z","date":"2023-06-08","kind":"purchase","planned":false,"acquired":true,"shares":6398,"price":3.9271,"value":25125.5858,"ownership":{"direct":false,"nature":"See Footnote (1)"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.775 to $4.22, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Shares held by Caissa Capital Management Ltd, a British Virgin Islands company controlled by Mr. Golestaneh."}],"balance_after":1395597,"source":{"system":"sec-edgar","filing":"0001929354-23-000013","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1929354/000192935423000013/primary_doc.xml","form_type":"4"}},{"id":1860953,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":111884,"kind":"organization","name":"Caissa Capital Management ltd.","position":1,"cik":"0001929354","reported_name":"Caissa Capital Management ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-06-09T16:24:16.000Z","date":"2023-06-07","kind":"purchase","planned":false,"acquired":true,"shares":2984,"price":3.4914,"value":10418.3376,"ownership":{"direct":false,"nature":"See Footnote (1)"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.90 to $3.6, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Shares held by Caissa Capital Management Ltd, a British Virgin Islands company controlled by Mr. Golestaneh."}],"balance_after":1389199,"source":{"system":"sec-edgar","filing":"0001929354-23-000013","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1929354/000192935423000013/primary_doc.xml","form_type":"4"}},{"id":1870390,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":111884,"kind":"organization","name":"Caissa Capital Management ltd.","position":1,"cik":"0001929354","reported_name":"Caissa Capital Management ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-06-02T16:22:32.000Z","date":"2023-05-31","kind":"purchase","planned":false,"acquired":true,"shares":844,"price":2.87,"value":2422.28,"ownership":{"direct":false,"nature":"See Footnote (1)"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Shares held by Caissa Capital Management Ltd, a British Virgin Islands company controlled by Mr. Golestaneh."}],"balance_after":1386215,"source":{"system":"sec-edgar","filing":"0001929354-23-000012","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1929354/000192935423000012/primary_doc.xml","form_type":"4"}},{"id":1875120,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":111884,"kind":"organization","name":"Caissa Capital Management ltd.","position":1,"cik":"0001929354","reported_name":"Caissa Capital Management ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common stock","published_at":"2023-05-30T16:27:36.000Z","date":"2023-05-30","kind":"purchase","planned":false,"acquired":true,"shares":671,"price":2.867,"value":1923.757,"ownership":{"direct":false,"nature":"See Footnote (1)"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.85 to $2.87, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Shares held by Caissa Capital Management Ltd, a British Virgin Islands company controlled by Mr. Golestaneh."}],"balance_after":1385371,"source":{"system":"sec-edgar","filing":"0001929354-23-000011","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1929354/000192935423000011/primary_doc.xml","form_type":"4"}},{"id":1875119,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":111884,"kind":"organization","name":"Caissa Capital Management ltd.","position":1,"cik":"0001929354","reported_name":"Caissa Capital Management ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common stock","published_at":"2023-05-30T16:27:36.000Z","date":"2023-05-25","kind":"purchase","planned":false,"acquired":true,"shares":2000,"price":2.77,"value":5540.0,"ownership":{"direct":false,"nature":"See Footnote (1)"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Shares held by Caissa Capital Management Ltd, a British Virgin Islands company controlled by Mr. Golestaneh."}],"balance_after":1384700,"source":{"system":"sec-edgar","filing":"0001929354-23-000011","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1929354/000192935423000011/primary_doc.xml","form_type":"4"}},{"id":1879979,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":111884,"kind":"organization","name":"Caissa Capital Management ltd.","position":1,"cik":"0001929354","reported_name":"Caissa Capital Management ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-05-24T16:15:01.000Z","date":"2023-05-24","kind":"purchase","planned":false,"acquired":true,"shares":5519,"price":2.9622,"value":16348.3818,"ownership":{"direct":false,"nature":"See Footnote (1)"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.92 to $3.03, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Shares held by Caissa Capital Management Ltd, a British Virgin Islands company controlled by Mr. Golestaneh."}],"balance_after":1382700,"source":{"system":"sec-edgar","filing":"0001929354-23-000010","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1929354/000192935423000010/primary_doc.xml","form_type":"4"}},{"id":1879978,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":111884,"kind":"organization","name":"Caissa Capital Management ltd.","position":1,"cik":"0001929354","reported_name":"Caissa Capital Management ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-05-24T16:15:01.000Z","date":"2023-05-24","kind":"purchase","planned":false,"acquired":true,"shares":3481,"price":3.0072,"value":10468.0632,"ownership":{"direct":false,"nature":"See Footnote (1)"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.0 to $3.01, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Shares held by Caissa Capital Management Ltd, a British Virgin Islands company controlled by Mr. Golestaneh."}],"balance_after":1377181,"source":{"system":"sec-edgar","filing":"0001929354-23-000010","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1929354/000192935423000010/primary_doc.xml","form_type":"4"}},{"id":1882886,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":111884,"kind":"organization","name":"Caissa Capital Management ltd.","position":1,"cik":"0001929354","reported_name":"Caissa Capital Management ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common stock","published_at":"2023-05-22T16:30:01.000Z","date":"2023-05-22","kind":"purchase","planned":false,"acquired":true,"shares":7000,"price":3.3368,"value":23357.6,"ownership":{"direct":false,"nature":"See Footnote (1)"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.00 to $3.72, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Shares held by Caissa Capital Management Ltd, a British Virgin Islands company controlled by Mr. Golestaneh."}],"balance_after":1373700,"source":{"system":"sec-edgar","filing":"0001929354-23-000009","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1929354/000192935423000009/primary_doc.xml","form_type":"4"}},{"id":1882885,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":111884,"kind":"organization","name":"Caissa Capital Management ltd.","position":1,"cik":"0001929354","reported_name":"Caissa Capital Management ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common stock","published_at":"2023-05-22T16:30:01.000Z","date":"2023-05-19","kind":"purchase","planned":false,"acquired":true,"shares":6500,"price":3.5157,"value":22852.05,"ownership":{"direct":false,"nature":"See Footnote (1)"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.4 to $3.6, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Shares held by Caissa Capital Management Ltd, a British Virgin Islands company controlled by Mr. Golestaneh."}],"balance_after":1366700,"source":{"system":"sec-edgar","filing":"0001929354-23-000009","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1929354/000192935423000009/primary_doc.xml","form_type":"4"}},{"id":1882884,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":111884,"kind":"organization","name":"Caissa Capital Management ltd.","position":1,"cik":"0001929354","reported_name":"Caissa Capital Management ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common stock","published_at":"2023-05-22T16:30:01.000Z","date":"2023-05-18","kind":"purchase","planned":false,"acquired":true,"shares":13121,"price":3.2896,"value":43162.8416,"ownership":{"direct":false,"nature":"See Footnote (1)"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.80 to $3.40, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Shares held by Caissa Capital Management Ltd, a British Virgin Islands company controlled by Mr. Golestaneh."}],"balance_after":1360200,"source":{"system":"sec-edgar","filing":"0001929354-23-000009","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1929354/000192935423000009/primary_doc.xml","form_type":"4"}},{"id":1891835,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":111884,"kind":"organization","name":"Caissa Capital Management ltd.","position":1,"cik":"0001929354","reported_name":"Caissa Capital Management ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common stock","published_at":"2023-05-16T17:23:43.000Z","date":"2023-05-16","kind":"purchase","planned":false,"acquired":true,"shares":379,"price":2.75,"value":1042.25,"ownership":{"direct":false,"nature":"See Footnote (1)"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Shares held by Caissa Capital Management Ltd, a British Virgin Islands company controlled by Mr. Golestaneh."}],"balance_after":1347079,"source":{"system":"sec-edgar","filing":"0001929354-23-000008","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1929354/000192935423000008/primary_doc.xml","form_type":"4"}},{"id":1891834,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":111884,"kind":"organization","name":"Caissa Capital Management ltd.","position":1,"cik":"0001929354","reported_name":"Caissa Capital Management ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common stock","published_at":"2023-05-16T17:23:43.000Z","date":"2023-05-15","kind":"purchase","planned":false,"acquired":true,"shares":1715,"price":2.5459,"value":4366.2185,"ownership":{"direct":false,"nature":"See Footnote (1)"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.45 to $2.79, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Shares held by Caissa Capital Management Ltd, a British Virgin Islands company controlled by Mr. Golestaneh."}],"balance_after":1346700,"source":{"system":"sec-edgar","filing":"0001929354-23-000008","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1929354/000192935423000008/primary_doc.xml","form_type":"4"}},{"id":1891833,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":111884,"kind":"organization","name":"Caissa Capital Management ltd.","position":1,"cik":"0001929354","reported_name":"Caissa Capital Management ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common stock","published_at":"2023-05-16T17:23:43.000Z","date":"2023-05-12","kind":"purchase","planned":false,"acquired":true,"shares":2285,"price":2.45,"value":5598.25,"ownership":{"direct":false,"nature":"See Footnote (1)"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Shares held by Caissa Capital Management Ltd, a British Virgin Islands company controlled by Mr. Golestaneh."}],"balance_after":1344985,"source":{"system":"sec-edgar","filing":"0001929354-23-000008","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1929354/000192935423000008/primary_doc.xml","form_type":"4"}},{"id":1901134,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":111884,"kind":"organization","name":"Caissa Capital Management ltd.","position":1,"cik":"0001929354","reported_name":"Caissa Capital Management ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-05-08T16:10:27.000Z","date":"2023-05-08","kind":"purchase","planned":false,"acquired":true,"shares":5000,"price":2.6216,"value":13108.0,"ownership":{"direct":false,"nature":"See Footnote (1)"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.575 to $2.68, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Shares held by Caissa Capital Management Ltd, a British Virgin Islands company controlled by Mr. Golestaneh."}],"balance_after":1342700,"source":{"system":"sec-edgar","filing":"0001929354-23-000007","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1929354/000192935423000007/primary_doc.xml","form_type":"4"}},{"id":1901133,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":111884,"kind":"organization","name":"Caissa Capital Management ltd.","position":1,"cik":"0001929354","reported_name":"Caissa Capital Management ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-05-08T16:10:27.000Z","date":"2023-05-05","kind":"purchase","planned":false,"acquired":true,"shares":5000,"price":2.875,"value":14375.0,"ownership":{"direct":false,"nature":"See Footnote (1)"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.85 to $2.9, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Shares held by Caissa Capital Management Ltd, a British Virgin Islands company controlled by Mr. Golestaneh."}],"balance_after":1337700,"source":{"system":"sec-edgar","filing":"0001929354-23-000007","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1929354/000192935423000007/primary_doc.xml","form_type":"4"}},{"id":1901132,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":111884,"kind":"organization","name":"Caissa Capital Management ltd.","position":1,"cik":"0001929354","reported_name":"Caissa Capital Management ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-05-08T16:10:27.000Z","date":"2023-05-04","kind":"purchase","planned":false,"acquired":true,"shares":15000,"price":2.7921,"value":41881.5,"ownership":{"direct":false,"nature":"See Footnote (1)"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.58 to $2.85, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Shares held by Caissa Capital Management Ltd, a British Virgin Islands company controlled by Mr. Golestaneh."}],"balance_after":1332700,"source":{"system":"sec-edgar","filing":"0001929354-23-000007","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1929354/000192935423000007/primary_doc.xml","form_type":"4"}},{"id":1912455,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":111884,"kind":"organization","name":"Caissa Capital Management ltd.","position":1,"cik":"0001929354","reported_name":"Caissa Capital Management ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-04-27T16:07:38.000Z","date":"2023-04-27","kind":"purchase","planned":false,"acquired":true,"shares":1504,"price":2.96,"value":4451.84,"ownership":{"direct":false,"nature":"See Footnote (1)"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.95 to $2.97, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Shares held by Caissa Capital Management Ltd, a British Virgin Islands company controlled by Mr. Golestaneh."}],"balance_after":1317700,"source":{"system":"sec-edgar","filing":"0001929354-23-000006","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1929354/000192935423000006/primary_doc.xml","form_type":"4"}},{"id":1912454,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":111884,"kind":"organization","name":"Caissa Capital Management ltd.","position":1,"cik":"0001929354","reported_name":"Caissa Capital Management ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-04-27T16:07:38.000Z","date":"2023-04-26","kind":"purchase","planned":false,"acquired":true,"shares":425,"price":2.97,"value":1262.25,"ownership":{"direct":false,"nature":"See Footnote (1)"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Shares held by Caissa Capital Management Ltd, a British Virgin Islands company controlled by Mr. Golestaneh."}],"balance_after":1316196,"source":{"system":"sec-edgar","filing":"0001929354-23-000006","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1929354/000192935423000006/primary_doc.xml","form_type":"4"}},{"id":1912453,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":111884,"kind":"organization","name":"Caissa Capital Management ltd.","position":1,"cik":"0001929354","reported_name":"Caissa Capital Management ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-04-27T16:07:38.000Z","date":"2023-04-25","kind":"purchase","planned":false,"acquired":true,"shares":5571,"price":2.9993,"value":16709.1003,"ownership":{"direct":false,"nature":"See Footnote (1)"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.97 to $3.05, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Shares held by Caissa Capital Management Ltd, a British Virgin Islands company controlled by Mr. Golestaneh."}],"balance_after":1315771,"source":{"system":"sec-edgar","filing":"0001929354-23-000006","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1929354/000192935423000006/primary_doc.xml","form_type":"4"}},{"id":1915008,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":111884,"kind":"organization","name":"Caissa Capital Management ltd.","position":1,"cik":"0001929354","reported_name":"Caissa Capital Management ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-04-24T16:32:46.000Z","date":"2023-04-24","kind":"purchase","planned":false,"acquired":true,"shares":12500,"price":3.0624,"value":38280.0,"ownership":{"direct":false,"nature":"See Footnote (1)"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.94 to $3.15, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Shares held by Caissa Capital Management Ltd, a British Virgin Islands company controlled by Mr. Golestaneh."}],"balance_after":1310200,"source":{"system":"sec-edgar","filing":"0001929354-23-000005","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1929354/000192935423000005/primary_doc.xml","form_type":"4"}},{"id":1915007,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":111884,"kind":"organization","name":"Caissa Capital Management ltd.","position":1,"cik":"0001929354","reported_name":"Caissa Capital Management ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-04-24T16:32:46.000Z","date":"2023-04-20","kind":"purchase","planned":false,"acquired":true,"shares":5000,"price":3.0783,"value":15391.5,"ownership":{"direct":false,"nature":"See Footnote (1)"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.94 to $3.14, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Shares held by Caissa Capital Management Ltd, a British Virgin Islands company controlled by Mr. Golestaneh."}],"balance_after":1297700,"source":{"system":"sec-edgar","filing":"0001929354-23-000005","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1929354/000192935423000005/primary_doc.xml","form_type":"4"}},{"id":1918305,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":111884,"kind":"organization","name":"Caissa Capital Management ltd.","position":1,"cik":"0001929354","reported_name":"Caissa Capital Management ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-04-18T16:08:00.000Z","date":"2023-04-18","kind":"purchase","planned":false,"acquired":true,"shares":10000,"price":2.9438,"value":29438.0,"ownership":{"direct":false,"nature":"See Footnote (1)"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.82 to $3.01, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Shares held by Caissa Capital Management Ltd, a British Virgin Islands company controlled by Mr. Golestaneh"}],"balance_after":1292700,"source":{"system":"sec-edgar","filing":"0001929354-23-000003","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1929354/000192935423000003/primary_doc.xml","form_type":"4"}},{"id":1918304,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":111884,"kind":"organization","name":"Caissa Capital Management ltd.","position":1,"cik":"0001929354","reported_name":"Caissa Capital Management ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-04-18T16:08:00.000Z","date":"2023-04-17","kind":"purchase","planned":false,"acquired":true,"shares":15000,"price":2.9624,"value":44436.0,"ownership":{"direct":false,"nature":"See Footnote (1)"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.60 to $3.09, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Shares held by Caissa Capital Management Ltd, a British Virgin Islands company controlled by Mr. Golestaneh"}],"balance_after":1282700,"source":{"system":"sec-edgar","filing":"0001929354-23-000003","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1929354/000192935423000003/primary_doc.xml","form_type":"4"}},{"id":1921895,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":111884,"kind":"organization","name":"Caissa Capital Management ltd.","position":1,"cik":"0001929354","reported_name":"Caissa Capital Management ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-04-11T16:51:36.000Z","date":"2023-04-11","kind":"purchase","planned":false,"acquired":true,"shares":25000,"price":2.8432,"value":71080.0,"ownership":{"direct":false,"nature":"See Footnote (1)"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.41 to $3.225, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Shares held by Caissa Capital Management Ltd, a British Virgin Islands company controlled by Mr. Golestaneh"}],"balance_after":1267700,"source":{"system":"sec-edgar","filing":"0001929354-23-000002","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1929354/000192935423000002/primary_doc.xml","form_type":"4"}},{"id":1921894,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":111884,"kind":"organization","name":"Caissa Capital Management ltd.","position":1,"cik":"0001929354","reported_name":"Caissa Capital Management ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-04-11T16:51:36.000Z","date":"2023-04-10","kind":"purchase","planned":false,"acquired":true,"shares":31329,"price":2.2802,"value":71436.3858,"ownership":{"direct":false,"nature":"See Footnote (1)"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.835 to $2.51, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Shares held by Caissa Capital Management Ltd, a British Virgin Islands company controlled by Mr. Golestaneh"}],"balance_after":1242700,"source":{"system":"sec-edgar","filing":"0001929354-23-000002","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1929354/000192935423000002/primary_doc.xml","form_type":"4"}}]}